Aberrant expression of FZD8 has been reported in gastric cancer, prostate cancer, renal cell carcinoma, lung cancer, pancreatic adenocarcinoma, and overexpression of FZD8 was considered to promote tumor metastasis (Li et al., 2017; Yang et al., 2017; Liu et al., 2019; Chen et al., 2020; Li et al., 2021). Here, FZD8 is linked to pancreatic adenocarcinoma.